The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of Core Laboratories Inc (NYSE: CLB) closed at $15.44 in the last session, down -4.40% from day before closing price of $16.15. In other words, the price has decreased by -$4.40 from its previous closing price. On the day, 0.55 million shares were traded. CLB stock price reached its highest trading level at $16.105 during the session, while it also had its lowest trading level at $15.415.
Ratios:
We take a closer look at CLB’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 28.05 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 20.94. For the most recent quarter (mrq), Quick Ratio is recorded 1.76 and its Current Ratio is at 2.37. In the meantime, Its Debt-to-Equity ratio is 0.62 whereas as Long-Term Debt/Eq ratio is at 0.57.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for the company, Citigroup on March 12, 2025, Upgraded its rating to Neutral and sets its target price to $16 from $15 previously.
On June 30, 2023, Citigroup Downgraded its rating to Sell which previously was Neutral and also lowered its target price recommendation from $22 to $21.
BofA Securities Downgraded its Neutral to Underperform on April 18, 2023, while the target price for the stock was maintained at $21.50.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLB now has a Market Capitalization of 718938688 and an Enterprise Value of 866452672. As of this moment, Core’s Price-to-Earnings (P/E) ratio for their current fiscal year is 22.75, and their Forward P/E ratio for the next fiscal year is 18.12. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.32. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.39 while its Price-to-Book (P/B) ratio in mrq is 2.62. Its current Enterprise Value per Revenue stands at 1.674 whereas that against EBITDA is 13.962.
Stock Price History:
The Beta on a monthly basis for CLB is 1.08, which has changed by -0.19047618 over the last 52 weeks, in comparison to a change of 0.15085125 over the same period for the S&P500. Over the past 52 weeks, CLB has reached a high of $21.76, while it has fallen to a 52-week low of $9.72. The 50-Day Moving Average of the stock is 16.06%, while the 200-Day Moving Average is calculated to be 18.96%.
Shares Statistics:
According to the various share statistics, CLB traded on average about 583.79K shares per day over the past 3-months and 582010 shares per day over the past 10 days. A total of 46.09M shares are outstanding, with a floating share count of 46.06M. Insiders hold about 1.08% of the company’s shares, while institutions hold 109.35% stake in the company. Shares short for CLB as of 1761868800 were 5515889 with a Short Ratio of 9.45, compared to 1759190400 on 6883429. Therefore, it implies a Short% of Shares Outstanding of 5515889 and a Short% of Float of 32.009998.
Dividends & Splits
The forward annual dividend rate for CLB is 0.04, which was 0.04 in the trailing 12 months. Against a Trailing Annual Dividend Yield of 0.0024767802. The stock’s 5-year Average Dividend Yield is 0.24. The current Payout Ratio is 5.97% for CLB, which recently paid a dividend on 2025-11-03 with an ex-dividend date of 2025-11-03. Stock splits for the company last occurred on 2010-07-09 when the company split stock in a 2:1 ratio.
Earnings Estimates
The market rating of Core Laboratories Inc (CLB) is currently shaped by the ongoing analysis conducted by 2.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.17, with high estimates of $0.17 and low estimates of $0.17.
Analysts are recommending an EPS of between $0.81 and $0.72 for the fiscal current year, implying an average EPS of $0.75. EPS for the following year is $0.83, with 3.0 analysts recommending between $0.92 and $0.74.
Revenue Estimates
According to 2 analysts,. The current quarter’s revenue is expected to be $128.58M. It ranges from a high estimate of $129.2M to a low estimate of $127.95M. As of. The current estimate, Core Laboratories Inc’s year-ago sales were $129.24MFor the next quarter, 2 analysts are estimating revenue of $126.47M. There is a high estimate of $126.47M for the next quarter, whereas the lowest estimate is $126.47M.
A total of 2 analysts have provided revenue estimates for CLB’s current fiscal year. The highest revenue estimate was $514.5M, while the lowest revenue estimate was $512.7M, resulting in an average revenue estimate of $513.6M. In the same quarter a year ago, actual revenue was $523.85MBased on 2 analysts’ estimates, the company’s revenue will be $535.72M in the next fiscal year. The high estimate is $550.5M and the low estimate is $520.95M.
